Retutatride 10 mg

Description

RETATRUTIDE 10 MG — Tri-agonist peptide GLP-1 / GIP / Glucagon

Scientific reference: LY3437943 | Presentation: 10 mg | Use: scientific research

Presentation

Retatrutide (LY3437943) is a next-generation experimental peptide developed by Eli Lilly. It stands out due to its triple agonism mechanism, simultaneously targeting three receptors involved in energy metabolism regulation: GLP-1, GIP, and glucagon. This innovative pharmacological architecture represents a major breakthrough in the study of biological mechanisms associated with glycemic balance, appetite regulation, and lipid metabolism.

Unlike agonists targeting one or two receptors, Retatrutide allows the exploration of the interaction of three complementary metabolic pathways within a single molecule.

Mechanism of action: three complementary metabolic pathways:

GLP-1 receptor — Satiety regulation Activation of the GLP-1 receptor plays a role in satiety signaling mechanisms, glucose-dependent insulin secretion, and gastric emptying slowing. GIP receptor — Metabolic response regulation GIP contributes to the regulation of insulin secretion and the coordination of metabolic responses after nutrient intake. Its association with GLP-1 is the subject of numerous scientific investigations. Glucagon receptor — Energy metabolism

Activation of the glucagon receptor plays a role in the regulation of hepatic metabolism and energy expenditure. Its integration into a tri-agonist molecule allows the study of interactions between energy substrate utilization, glucose homeostasis, and lipid metabolism. Data from clinical research

Retatrutide has been the subject of several clinical investigation programs focusing notably on obesity and metabolic disorders. A phase 2 study published in the New England Journal of Medicine in 2023 reported an average body weight reduction of up to 24.2% after 48 weeks, in the group receiving the highest experimental dose studied.

These results concern participants followed in a controlled clinical environment. They do not constitute a guarantee of individual effectiveness or authorization for therapeutic use.

Laboratory presentation — 10 mg The 10 mg Retatrutide format corresponds to a lyophilized presentation intended for authorized analytical and experimental research work. Lyophilization facilitates the storage and handling of the substance in an appropriate laboratory environment. This presentation can be used, in particular, in the context of work on: * The characterization of multi-agonist peptides. * The study of interactions with GLP-1, GIP, and glucagon receptors. * The analysis of metabolic signaling pathways. * Analytical methods for the characterization and stability of peptides.

Technical characteristics Parameter Specification Designation Retatrutide Research reference LY3437943 Family Tri-agonist peptide Targeted receptors GLP-1 / GIP / Glucagon Presentation 10 mg vial Form Lyophilized powder Purity analysis HPLC Documentation Certificate of analysis depending on batch availability Destination Scientific research only Quality control and traceability The analytical characterization of batches may include HPLC chromatographic analysis as well as identity confirmation by mass spectrometry. The exact purity values, analytical results, and identification of the testing laboratory must be established from the certificate of analysis corresponding to the batch in question.

Retatrutide 10 mg — LY3437943 | GLP-1 / GIP / Glucagon Tri-agonist Peptide | Scientific research

Product information

Name

Retutatride 10 mg

SKU

UL-RC-002

Category

Weight Loss and Body Recomposition

Format

10 mg

Catalogue price

84 €

Availability

Available

Container

Glass vial

Batch information

Batch number

RETA-2026-10

Batch date

Oct 2026

Certificate of analysis

• Certificate of analysisBatch DEMO-2026-0102

  Placeholder

  Laboratory

  Placeholder laboratory

  Date

  2 Aug 2026

  Results

  Not supplied

  Open PDF

Storage

Storage and Handling Lyophilized Retatrutide should be stored in accordance with the stability conditions documented by the manufacturer and the laboratory's procedures. The shelf life, temperature conditions, and stability after reconstitution must be determined based on validated data for the relevant formulation and batch. Any handling must be performed by qualified personnel in an environment suitable for experimental substances. Documentation and Traceability Each batch must be identifiable by its production reference and the corresponding analytical documents. Traceability information may include the batch number, manufacturing date, quality control methods, and applicable storage conditions. Scientific Warning Retatrutide is an experimental substance. This presentation is exclusively intended for authorized scientific research. It is not intended for self-medication, human or animal administration outside a regulated research framework.